Additional file 2 of Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

Additional file 2: Table S1. List of heavy peptides assayed by PRM with relative retention times (RT) and solubilization conditions. Table S2. List of heavy peptides used in the verification experiments and relative concentration in the heavy peptide mixture (HPM). Table S3. LC-MS/MS PRM method for the acquisition of 163 samples. Table S4. Peptides used as normalization factors